Ann: Completion of Enrolment in SMARTCOUGH-C Study, page-27

Three market sensitive announcements expected in the next 5 weeks:
1) Updated Australian paediatric clinical study results;
2) Top line results from US clinical trials. This will be a massive catalyst;
3) FDA submission for first product.

Management have taken no chances...top research team, top cornerstone investors, top awards, top hospitals, top NGO trialling in developing countries, top CRO's, top FDA consultant with top FDA approval record.

I expect the top line results to catch many by surprise. There will be huge media and analyst coverage and it will result in a massive momentum shift and share price upside breakout from this 6 month trading range. IMO we can expect share prices in the 0.50 - 0.80 range by end of year. GLTA.